FDA Inspection
Glaxo Operations U.K. Ltd.Glaxo Operations U.K. Ltd. – FDA Inspection, Jun 2, 2017
Record Details
This FDA Inspection record concerns Glaxo Operations U.K. Ltd., with an inspection on June 2, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 650fa308-f844-4b69-aa5d-3e08cca79293
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1014765
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Glaxo Operations U.K. Ltd.
10| Date | Classification | Office | Project area |
|---|---|---|---|
| March 16, 2023 | Not classified | Office of Inspections and Investigations | |
| February 10, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 17, 2019 | VAI | Office of Inspections and Investigations | New Drug Evaluation |
| July 4, 2017 | Not classified | Office of Inspections and Investigations | |
| June 23, 2015 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Glaxo Operations U.K. Ltd.
- FDA Inspection 1211398 - 2023-03-16
- FDA Inspection 1209851 - 2023-02-10
- FDA Inspection 1107134 - 2019-09-17
- FDA Inspection 1016930 - 2017-07-04
- FDA Inspection 933676 - 2015-06-23
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.